FDA approves Afinitor to treat brain tumours
The US Food and Drug Administration (FDA) has approved Novartis Afinitor (everolimus) tablets to treat adults and children with benign brain tumours associated with tuberous sclerosis.
The US Food and Drug Administration (FDA) has approved Novartis’ Afinitor (everolimus) tablets to treat adults and children with benign brain tumours associated with tuberous sclerosis (TS), a genetic disorder that may cause tumours to form in vital organs. Prior to the approval of Afinitor, Novartis says brain surgery was the only treatment option for patients with growing Subependymal giant cell astrocytoma (SEGA) tumours. The approval is based on a 28-patient study conducted by Cincinnati Children''s Hospital Medical Center in the US, which showed that nearly one-third of patients (32%) experienced a reduction of 50% or greater in the size of their largest SEGA tumours after six months. A Phase III study is underway that compares Afinitor to placebo to explore its clinical benefits for the treatment of patients with SEGA associated with TS. Tuberous sclerosis is a genetic disorder affecting approximately 25,000–40,000 people in the US. SEGAs occur in up to 20% of patients wit
Related News
-
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Biden's $2 billion Biotech Boost
President Biden issues executive order to bolster U.S. biomanufacturing sector. -
News US FDA grants priority review for Eisai and Biogen's Alzheimer's drug
Decision by US drug regulator on lecanemab expected by early next year -
News Panaxia's medical cannabis facility in Malta gains EU-GMP standard
This second facility gives the company a significant power multiplier for export capacity and geographical reach -
News CPHI Discover: Remote excipient audits are on the increase, but we must do more to develop novel excipients
Ahead of the session, Value Added Excipients to Unlock the Potential of APIs, at CPHI Discover on Thursday 18th May – global pharma’s largest ever virtual gathering – we spoke with one of the speakers, Dr Iain Moor...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance